Clinical trials: Epilepsy Idiopathic
Epilepsy, Epilepsy, Idiopathic Generalized
Idiopathic Generalized Epilepsy Syndromes
The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized…
- Trial name
- NCT06388174
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shen Chun-Hong
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy, Unspecified, Intractable
Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody
The purpose of the study is to investigate effect of immunotherapy in intractable cryptogenic epilepsy patients with autoimmune antibody.
- Trial name
- NCT02695797
- Testing
- IVIG, Prednisolone
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Infantile Spasms, Refractory Complex Partial Seizures in Adults
Sabril Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with Sabril and the prescribers of Sabril.
- Trial name
- NCT01073579
- Testing
- Sabril®
- Volunteers
- 9,423 people
- Sponsor
- Lundbeck LLC
Asymptomatic Subjects With Atopy and Elevated Serum IgE
The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels
The aim of this study was to evaluate the efficacy of PG102 at lowering levels of total IgE in asymptomatic subjects with atopy.
- Trial name
- NCT01106703
- Testing
- PG102, a water soluble extract from Actinidia arguta
- Where
- 2 sites in South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Epilepsy, Focal Epilepsy
Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
This is a national monocentric (San Raffaele Hospital - OSR, Via Olgettina, 60, 20132 Milan, Italy) observational low-risk-intervention study, prospective and multiparametric (clinical, EEG, neuropsychological evaluations) study.
- Trial name
- NCT06210022
- Testing
- Neuropsychological Assessment
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- IRCCS San Raffaele
Epilepsy
A Study of Fycompa (Perampanel) in Korean Participants
The purpose of this post-marketing surveillance is to observe the following items regarding the safety profile of Fycompa (Perampanel) film-coated tablets and oral suspension in normal clinical practice setting: serious adverse…
- Trial name
- NCT02722590
- Where
- 9 sites in South Korea
- Volunteers
- 3,692 people
- Sponsor
- Eisai Korea Inc.
Epilepsy, Idiopathic Generalized
Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
This study is an open-label, active-controlled,non-inferiority trial comparing efficacy and safety of levetiracetam versus valproate in idiopathic generalized tonic-clonic epilepsy.
- Trial name
- NCT03940326
- Testing
- Levetiracetam, Valproate
- Where
- Iran
- Volunteers
- 103 people
- Sponsor
- Mazandaran University of Medical Sciences
Benign Childhood Epilepsy With Centro-temporal Spikes (BCECTS), Focal Cryptogenic Epilepsy of Childhood
Brain Maturation in Children With Localization Related Epilepsy
This project intends to investigate children with idiopathic and cryptogenic localization related epilepsies, using a longitudinal assessment of structural and functional MRI data, in relation to neuropsychological evaluation.
- Conditions
- Benign Childhood Epilepsy With Centro-temporal Spikes (BCECTS), Focal Cryptogenic Epilepsy of Childhood, Cryptogenic Epilepsy of Childhood
- Trial name
- DYNAMAT (NCT02648529)
- Testing
- MRI, functional MRI (fMRI), neuropsychological assessment
- Where
- France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Intractable Epilepsy, Convulsive Seizures
Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy
Although corticosteroids have been shown to be beneficial anecdotally for refractory epilepsy, the effects of corticosteroids on pediatric epilepsy have primarily been studied retrospectively amongst a heterogeneous patient…
- Trial name
- NCT04219995
- Testing
- methylprednisolone sodium succinate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Idiopathic Generalized Epilepsy
Human Epilepsy Project 3
By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try…
- Trial name
- HEP3 (NCT05374928)
- Where
- 18 sites in United States, Australia
- Volunteers
- 316 people
- Sponsor
- NYU Langone Health
Temporal Lobe Epilepsy
Advanced Magnetic Resonance Imaging in Temporal Lobe Epilepsy
We aim to o evaluate the role of conventional and advanced MRI sequences in diagnosis of idiopathic temporal lobe epilepsy including identification and lateralization of epileptogenic focus.
- Trial name
- NCT03643471
- Testing
- MRI
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Study the Efficacy of Epidiolex for Typical Absence Seizures
Epidiolex in Typical Absence Seizures
This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period…
- Trial name
- NCT04899050
- Testing
- Cannabidiol (Epidiolex)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Epilepsy Idiopathic, Clinical Disease and/or Syndrome
Omics-based Precision Medicine of Epilepsy
Epilepsy is a major disease of the nervous system (WHO, 2015), as well as the second most common neural disease. It has been recorded that there have been 65 million epilepsy patients all over the world, more than 10 million in…
- Conditions
- Epilepsy Idiopathic, Clinical Disease and/or Syndrome, Gene Mutation
- Trial name
- NCT03358459
- Testing
- non
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Fudan University
Epilepsy
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy…
- Trial name
- VALOR (NCT02408523)
- Testing
- Lacosamide Tablet, Lasosamide Oral Solution
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 242 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Cenobamate Open-Label Extension Study for YKP3089C025
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
- Trial name
- NCT03961568
- Testing
- Cenobamate
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- SK Life Science, Inc.
Localization-Related (Focal) (Partial) Idiopathic Epilepsy and Epileptic Syndromes With Seizures of Localized Onset, TRAIL: Tumor Necrosis Factor Related Apoptosis Inducing Ligand MCP-2
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure
1. Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. 2. Possible role to predict the prognosis of patients with epileptic seizure.
- Conditions
- Localization-Related (Focal) (Partial) Idiopathic Epilepsy and Epileptic Syndromes With Seizures of Localized Onset, TRAIL: Tumor Necrosis Factor Related Apoptosis Inducing Ligand MCP-2, MCP-2: Monocyte Chemo-attractant Protein-2
- Trial name
- seizure (NCT05571371)
- Testing
- Measuring inflammatory serum biomarkers
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Esraa Mostafa Ahmed Abdel Aal
Idiopathic Generalized Epilepsy
Blinking and Yawning in Epilepsy: The Role of Dopamine
The objective of the present study is to assess dopaminergic reactivity with behavioural markers (i.e. yawning and blinking) in patients with idiopathic generalized epilepsy compared to matched healthy controls, after injection…
- Trial name
- BYE BYE DOPA (NCT01432821)
- Testing
- Apomorphine (Experimental product)
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Primary Generalized Epilepsy
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures.
- Trial name
- NCT03678753
- Testing
- Cenobamate
- Where
- 116 sites in United States, Australia and 10 more
- Volunteers
- 169 people
- Sponsor
- SK Life Science, Inc.
Allergic Asthma
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that…
- Trial name
- NCT00267202
- Testing
- Omalizumab, Immunotherapy
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis